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Hypericum perforatum is a perennial plant, with worldwide distribution, commonly
known as St. John’s wort. It has been used for centuries in traditional medicine
for the treatment of several disorders, such as minor burns, anxiety, and mild to
moderate depression. In the past years, its antidepressant properties have been
extensively studied. Despite that, other H. perforatum biological activities, as its
neuroprotective properties have also been evaluated. The present review aims to
provide a comprehensive summary of the main biologically active compounds of
H. perforatum, as for its chemistry, pharmacological activities, drug interactions and
adverse reactions and gather scattered information about its neuroprotective abilities. As
for this, it has been demonstrated that H. perforatum extracts and several of its major
molecular components have the ability to protect against toxic insults, either directly,
through neuroprotective mechanisms, or indirectly, through is antioxidant properties.
H. perforatum has therefore the potential to become an effective neuroprotective
therapeutic agent, despite further studies that need to be carried out.
Keywords: Hypericum perforatum, extracts, compounds, neuroprotection, antioxidant activity
INTRODUCTION
Hypericum perforatum, also known as St. John’s wort, hypericum or millepertuis is a member of the
family Hypericaceae and a herbaceous perennial plant native Europe, western Asia, and northern
Africa. Nowadays it has a worldwide distribution. The crude drug, called herba hyperici, consists
of the upper aerial parts of the plant collected just before or during the flowering period (Barnes
et al., 2001; Greeson et al., 2001; Patocka, 2003).
Hypericum perforatum has been used as a medicinal plant for centuries, for the treatment of
external and internal disorders. Externally, oily preparations of the plant may be applied to treat
minor burns, wounds, skin inflammation, and nerve pain (Barnes et al., 2001; Greeson et al., 2001;
Patocka, 2003). Internally, it is indicated for the treatment of anxiety and mild to moderately severe
depression (Barnes et al., 2001; Greeson et al., 2001; Patocka, 2003; Butterweck and Schmidt, 2007)
competing for status as a standard antidepressant therapy and being the only herbal alternative to
synthetic antidepressants (Wurglics and Schubert-Zsilavecz, 2006).
Hypericum perforatum contains several classes of biologically active compounds. These
constituents often vary in its concentration, due to genetic variation within the species and/or
adulteration, ecological factors, time of harvesting, preparation and processing of sample
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material and storage conditions, such as exposure to light, time
of harvesting. Important bioactive components are concentrated
in buds, blossoms, and tips of twigs. Despite this variation, it
is known that around 20% of the plant extract is comprised of
bioactive compounds (Nahrstedt and Butterweck, 1997; Patocka,
2003; Wurglics and Schubert-Zsilavecz, 2006; Linde, 2009).
PHARMACOLOGICAL ACTIVITY OF
Hypericum perforatum
St John’s wort most investigated pharmacological activity has
been its antidepressant properties. There are several reports
of higher H. perforatum effectiveness compared to placebo
intake and a similar activity, when comparing to several
antidepressant drugs. The exact mechanism of H. perforatum’s
antidepressant activity is still unclear, as to which are the
most relevant constituents. Early in vitro research suggested an
antidepressant activity due to hypericin, through the inhibition
of the monoamine oxidase (MAO) enzyme (Suzuki et al., 1984;
De Vry et al., 1999; Gaster and Holroyd, 2000; Behnke et al.,
2002; Linde et al., 2005; Linde, 2009; Rahimi et al., 2009).
However, its concentration was too low to explain the clinical
effects (Butterweck, 2003) detected. Further studies showed that
hyperforin was capable of inhibiting the reuptake of serotonin,
dopamine, noradrenaline, GABA, and L-glutamate (Chatterjee
et al., 1998). Antidepressive activity was also reported in several
flavonoids. Taking all these results in consideration and the fact
that the mechanisms underlying depression are still not well
understood, it is more likely that H. perforatum’s antidepressant
activity is due to a multiplicity of bioactive compounds and not to
a single constituent and/or mechanism of action (Greeson et al.,
2001; Butterweck and Schmidt, 2007; Nahrstedt and Butterweck,
2010).
Hypericum perforatum also presents antimicrobial properties.
Regarding the antibacterial activity, crude plant extracts of the
aerial parts of the plant, fractions and isolated compounds have
been tested, demonstrating positive results. Concerning specific
compounds, hyperforin is reported to present antibacterial
activity against Staphylococcus aureus and Gram-positive
bacteria, such as Streptococcus pyogenes and Corynebacterium
diphtheriae being considered the antibacterial agent of
H. perforatum. As for antifungal properties the flavonoids
quercitrin, hyperoside, avicularin, rutin, quercetin, and
kaempferol were reported to present antifungal activity against
Helminthosporium sativum (Schempp et al., 1999; Reichling
et al., 2001; Saddiqe et al., 2010). Another compound extendedly
studied, in what concerns its antimicrobial, more specifically,
antiviral activity, is hypericin. This naphtodianthrone has
demonstrated in vitro antiviral activity against a variety of
viruses, light and oxygen influenced (Kubin et al., 2005). The
in vivo studies did not, however, retrieve as promising results,
possibly due to differences in terms of light irradiation (Karioti
and Bilia, 2010) in many regions of the human body.
Besides its antiviral properties, hypericin has aroused
interest in the scientific community for its antitumoral activity.
Since hypericin is probably the most powerful photosensitizer
found in nature and for its specific properties, such as a
strong absorption at longer wavelength, minimal dark toxicity,
certain tumor selectivity and much higher clearance rate
from the host body than hematoporphyrins, its potential
for antitumoral photodynamic therapy has been explored
in several studies (Agostinis et al., 2002; Miskovsky, 2002;
Martinez-Poveda et al., 2005b). Hyperforin and its stable,
hydrosoluble derivate, aristoforin has also been reported
to possess antitumoral activity, namely anticarcinogenic,
antiproliferative, proapoptotic, antiinvasive, antimetastatic, and
antiangiogenic effects (Hostanska et al., 2003; Schwarz et al.,
2003; Dona et al., 2004; Martarelli et al., 2004; Gartner et al.,
2005; Martinez-Poveda et al., 2005a; Rothley et al., 2009).
Anti-inflammatory, wound healing and anti-nociceptive
effects have also been associated with H. perforatum
(Motallebnejad et al., 2008; Suntar et al., 2010).
Hypericum perforatum–Drug
Interactions and Adverse Reactions
A number of clinically significant pharmacokinetic and
pharmacodynamic interactions have been reported (Henderson
et al., 2002) over the years suggesting that H. perforatum use
concomitantly with several other drugs may represent its most
relevant risk (Knuppel and Linde, 2004). These interactions are
possibly due to a modulation of isoenzymes of the cytochrome
P450 (CYP; Borrelli and Izzo, 2009), which metabolizes a series of
pharmaceutical substances and an induction of P-glycoprotein,
which is responsible for an increase of drugs’ excretion from the
organism (Muller, 2003). Table 1 summarizes the most known
interactions.
As to what adverse reactions concerns, H. perforatum is
referred to as generally well tolerated. When side effects occur
they are considered mild and transient. The most common are
gastrointestinal symptoms, dizziness, confusion, fatigue and/or
sedation, skin reactions, restlessness or anxiety, headache, dry
mouth and allergic reactions. These may occur in 1–3% of
patients taking H. perforatum. There have also been described
rare adverse reactions that include phototoxicity. Symptoms
indicative of phototoxicity include dermal erythema, rash,
and pruritus. These adverse reactions have been attributed
to naphthodianthrones. Other rare adverse reactions described
comprehend alopecia, neuropathy and mania (Barnes et al., 2001;
Greeson et al., 2001; Hammerness et al., 2003; Schulz, 2006;
Wurglics and Schubert-Zsilavecz, 2006; Russo et al., 2013).
NEUROPROTECTIVE ACTIVITY AND
Hypericum perforatum
The Central Nervous System (CNS) is known for being parti-
cularly sensitive to oxidative stress, which can be described as
an imbalance between generation and elimination of reactive
oxygen species (ROS) and reactive nitrogen species (RNS). This
particular susceptibility of the brain is caused by a high metabolic
rate, a low concentration of glutathione and antioxidant enzyme
catalase (CAT) and a high proportion of polyunsaturated fatty
acids. The general inability of neurons to divide explains some
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TABLE 1 | Hypericum perforatum–drug interactions.
Drug Possible interaction Type of interaction Reference
Warfarin Induction of CYP1A2 and CYP2C9 Pharmacokinetic Karminsky and Zhang, 1997;
Hammerness et al., 2003
Cyclosporin Induction of CYP3A4 and P-glycoprotein transport Pharmacokinetic Henderson et al., 2002;
Hammerness et al., 2003
Risk of transplant rejection Pharmacodynamic Muller, 2003
Oral contraceptives Induction CYP1A2 and CYP3A4 Pharmacokinetic Ball et al., 1990; Schmider
et al., 1997
Inhibition of CYP2C9 and CYP2C19 Pfrunder et al., 2003
Theophylline Induction of CYP1A2 and CYP2C9 and P-glycoprotein
transport
Pharmacokinetic Henderson et al., 2002;
Hammerness et al., 2003;
Wurglics and
Schubert-Zsilavecz, 2006
Digoxin Induction of CYP2C9, CYP2D6, CYP3A4, CYP1A2,
CYP2C19, affecting P-glycoprotein transport, and
reduction of drug’s plasmatic concentration
Pharmacokinetic Barnes et al., 2001; Greeson
et al., 2001; Henderson et al.,
2002
HIV protease inhibitors Induction of CYP3A4 Pharmacokinetic Piscitelli et al., 2000
HIV non-nucleoside reverse
transcriptase inhibitors
Induction of CYP3A4 Pharmacokinetic Henderson et al., 2002;
Hammerness et al., 2003
Anticonvulsivants Induction of CYP2C9, CYP3A4, CYP1A2, and affecting
P-glycoprotein transport
Pharmacokinetic Barnes et al., 2001; Henderson
et al., 2002
Phenprocoumon Induction of CYP2C9, CYP2D6, CYP3A4, CYP1A2,
CYP2C19, and affecting P-glycoprotein transport
Pharmacokinetic Barnes et al., 2001
Nifedipin Induction of CYP3A4; Pharmacokinetic Hammerness et al., 2003
Induction of CYP3A4 and CYP2C19 Wang et al., 2007
Statins Induction of CYP3A4; Pharmacokinetic Hammerness et al., 2003
Induction of P-glycoprotein transport Holtzman et al., 2006
Midazolam Induction of CYP3A4; Pharmacokinetic Hammerness et al., 2003
Verapamil Induction of first-pass CYP3A4 metabolism Pharmacokinetic Russo et al., 2013
Omeprazol, esomeprazole, and
pantoprazole
Induction of CYP2C19 Pharmacokinetic Wang et al., 2004
Loperamide Theoretical induction of monoamine oxidase
inhibitor-drug reaction
Pharmacokinetic Khawaja et al., 1999
Ibuprofen Increase of expression of glycoprotein G Pharmacokinetic Russo et al., 2013
Dexamethasone, prednisone, and
budesonide
Induction of CYP3A4 Pharmacokinetic Russo et al., 2013
Methadone and pethidine Induction of CYP2D2 Pharmacokinetic Dostalek et al., 2005
Dextromethorphan and oxicodone Induction of CYP3A4 Pharmacokinetic Nieminen et al., 2010
Voriconazole Induction of CYP3A4, CYP2C19, and CYP2C9 Pharmacokinetic Borrelli and Izzo, 2009
Erythromycin Induction of CYP3A4 Pharmacokinetic Borrelli and Izzo, 2009
Imatinib Induction of CYP3A4 and P-gp Pharmacokinetic Smith et al., 2004
Triptans Risk of increased serotoninergic effects with the
possibility of an increased risk of adverse reactions
Pharmacodynamic Barnes et al., 2001; Henderson
et al., 2002; Hammerness
et al., 2003
Selective serotonin reuptake inhibitors Risk of increased serotoninergic effects with the
possibility of an increased risk of adverse reactions
Pharmacodynamic Barnes et al., 2001; Greeson
et al., 2001; Henderson et al.,
2002; Hammerness et al., 2003
Antineoplastic drugs directed against to
topoisomerase II alpha
May antagonize therapeutic activity of the drugs Pharmacodynamic Hammerness et al., 2003
Thyroid agentes Increase in thyroid-stimulating hormone Pharmacodynamic Ferko and Levine, 2001; Russo
et al., 2013
aging and neurodegenerative disease related loss of function,
as neurons die, without chance to be replaced. Apoptosis and
excitotoxicity are among the mechanisms that cause neuronal
death, involving ROS and RNS Therefore oxidative stress plays
an important role in the development of neurodegenerative
diseases, such as Alzheimer’s and Parkinson’s disease and stroke.
In order to prevent these cause-dependent diseases it is important
to preserve redox environment and mitochondrial function of
the cell. This can be achieved by avoiding the causes of oxidative
stress and strengthen the defenses with the usage endogenous
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antioxidants and the intake of others. Endogenous antioxidants
include enzymatic and non-enzymatic defenses. Enzymatic
antioxidants react with reactive species and are, subsequently,
efficiently recycled, preventing most of the formation of the toxic
free radicals. Only small amounts of these enzymes are therefore
needed to offer protection. Relevant enzymatic antioxidants are
Se-glutathione peroxidase (GPx), CAT, and superoxide dismutase
(SOD) that metabolizes superoxide, hydrogen peroxide (H2O2),
and lipid peroxides. Non-enzymatic defenses can be divided
in hydrophobic and hydrophilic antioxidants. Lipophilic
antioxidants comprise α-tocoferol, carotenoids, and ubiquinone-
10 and are mostly present in membranes and lipoproteins.
Hydrophilic antioxidants include glutathione, histone-peptides,
the iron-binding proteins transferring and ferritin, dihydrolipoic
acid, melatonin, uric acid, and ascorbic acid. They can be found
in cytosolic, mitochondrial, and nuclear aqueous compartments.
These defense mechanisms are complementary to each other,
due to the different species and cellular compartments that they
act against. Exogenous antioxidants include several vitamins,
such as A, E, and C, carotenoids and polyphenolic compounds,
such as flavonoids (Pietta, 2000; Emerit et al., 2004; Silva et al.,
2005; Zhao, 2005; Silva B.A. et al., 2008; Butterfield et al., 2007;
Boots et al., 2008; Ansari et al., 2009).
Besides their usage in the prevention of neurodegenerative
diseases, antioxidants could also be relevant on its treatment, as
a single compound or in supplementary combination with drugs
targeting other pathogenic mechanisms (Behl, 1999).
Neuroprotective Activity of Hypericum
perforatum Extracts
Lu et al. (2004) reported a neuroprotective effect of standard
H. perforatum extracts on H2O2 trauma induced by an optimum
concentration of 200 µM in rat pheochromocytome cell line
PC12 (cell line widely used in in vitro model of neuronal
injury and oxidative stress (Sasaki et al., 2003; Zou et al., 2010)
within 24 h treatment. The extract improved the survival rate
of neural cells, in a dose-dependent manner, at concentrations
of 1 ∼40 µg/mL, with a 133% improvement at 40 µg/mL.
In extract concentrations ranging from 60 to 100 µg/mL, a
decrease in cell viability was reported, maintaining, however,
higher viability levels, when comparing to control (p < 0.05).
H. perforatum extract, at concentrations of 1∼100 µg/mL also
decreased intra- and extracellular ROS levels, at 71 and 50%,
respectively, when comparing to the control group. This is
indicative of a limitation in the intracellular ROS generation
during cell aerobic metabolism and of the extract’s entrance in
the cells, with a consequent reduction of ROS levels. There also
was reported a block in DNA fragmentation of H2O2-induced
apoptosis (which reflects the endonuclease activity characteristic
of apoptosis) at concentrations of 10 to 100 µg/mL (Lu et al.,
2004; Zou et al., 2010). These results are in accordance with
those described by Benedi et al. (2004) but with an insult of
300 µM H2O2. Pre-treatment with the standardized extract also
attenuated caspase-3 activity, increased by H2O2 insult. Caspases,
of which caspase-3 is the most widely studied, are a class of
cysteine proteases, considered of extreme importance in the
apoptotic process, triggering a proteolytic cleavage cascade in
mammalian cells (Cohen, 1997).
Using the same biological model and insult, a flavonoid-rich
extract, particularly in rutin, hyperoside, isoquercetin, avicularin,
and quercitrin (Zou et al., 2004), proven significant protective
effects against induced apoptosis, in the studied concentrations
above 6.25 µg/mL (Zou et al., 2010). Similar results (regarding
induced-apoptosis protection and attenuation of caspase 3-
activity) have been described for a H. perforatum’s methanolic
dried extract in human neuroblastoma cell line SK-N-MC.
There was also observed, under the phase-contrast microscope,
that cells treated with H2O2 (at a concentration of 10−10mM)
for 5 h were detached from the dish, with cell rounding,
cytoplasmic blebbing, and irregularity in shape. All of the
morphological alterations described were less frequent among
cells pre-treated with H. perforatum. The DAPI assay revealed
nuclear condensation, DNA fragmentation, and perinuclear
apoptotic bodies under the same treatment conditions with
H2O2. The appearance of cells pre-treated with H. perforatum
was, like described above, closer to that of control (Jang et al.,
2002). H. perforatum standardized extract has also been described
to have the ability to protect against enzymatic and non-
enzymatic lipid peroxidation in rat brain, inhibiting NADPH-
dependent lipid peroxidation and attenuating of non-enzymatic
Fe2+/ascorbate-dependent lipid peroxidation in cerebral cortex
mitochondria. Inhibition of lipid peroxidation was reported to
be the results of the extract’s scavenging effect on NADPH and
Fe2+/ascorbate generated free radicals (Benedi et al., 2004).
Glutamate, a neurotransmitter, which extracellular accumu-
lation leads to overstimulation of postsynaptic glutamate
receptors, with consequent inhibition of intracellular glutathione
synthesis and Ca2+ overload, can act as a toxic, leading to
cell death (Ankarcrona et al., 1995; Breyer et al., 2007). Taking
this in consideration Breyer et al. (2007) investigated the
neuroprotective activity of H. perforatum extract in glutamate-
induced cell death in hippocampal HT22 nerve cell line. Pre-
incubation for 2–25 h with the extract and/or simultaneous
incubation with glutamate and extract-incubation of the cells up
to 8 h after glutamate exposition prevented cell death. There
is no statistically significant difference between the control cells
and the cells pre and co-incubated with the extract, whereas
the glutamate-exposure cells decrease in cell viability more than
80%. It was also demonstrated that H. perforatum extract was
able to counteract the energy losses induced by the glutamate.
The authors concluded that the extract protected HT22 cells
from glutamate-induced cytotoxicity by reducing or attenuating
glutathione loss, calcium fluxes, energy status, and ROS-mediated
cell death, but only up to 8 h after glutamate exposition.
Alzheimer’s disease is characterized by neuronal degeneration,
particularly of pyramidal hippocampal neurons, entorhinal
cortex, and other neocortical areas, which include the specific loss
of cholinergic neurons in the median forebrain (Bains and Shaw,
1997). Besides that, two hallmarks of this neurodegenerative
disorder are neurofibrillary tangles and senile plaques (Silva et al.,
2004), the last mainly constituted by amyloid protein fibers,
derived from an amyloid precursor protein, arranged in a so-
called cross-β-pleated sheet conformation. This heterogeneous
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peptide in size is proven to be neurotoxic and this general
toxicity appears mediated in some part by oxidative stress (Behl,
1999; Behl and Moosmann, 2002; Ansari et al., 2009). In fact,
amyloid-β-induced toxicity on neuronal cells is proposed as a
main route to neuronal loss in Alzheimer’s disease (Butterfield
et al., 2007). Taking this in consideration and the protective
characteristics of H. perforatum extracts, Silva et al. (2004)
studied its potential neuroprotective action in β-amyloid-induced
cell toxicity, through lipid peroxidation and Syto-13/PI assay.
After incubating hippocampal wistar rat neurons with non-
toxic concentrations of ethanolic extract H. perforatum and
fractions, a significant inhibition of ascorbate/Fe2+-induced
lipid peroxidation was observed on the fractions containing
caffeoylquinic acids and flavonol glycosides, flavonol glycosides
(quercetin-type), flavonol and biflavone aglycones and several
phenols (19, 21 (p < 0.05), 77, and 98% (p < 0.001),
respectively). H. perforatum extract and the fractions containing
bianthraquinones, flavonol glycosides and flavonol and biflavone
aglycones significantly inhibited lipid peroxidation, after cell
incubation with β-amyloid(25−35) 25 µM (p < 0.001), with
levels lower than the control basal peroxidation. Cell viability
was determined by Syto-13/PI assay. H. perforatum ethanolic
extract and fractions containing flavonol glycosides, flavonol,
and biflavone aglycones reduced cell death [65, 58, and
59%, respectively, when comparing to control (p < 0.001)].
Morphological analysis with cells stained with cresyl violet
showed that after cell exposure to amyloid β-peptide a pattern
of neuronal death was observed, specifically by a decrease in cell
volume, nuclear condensation, appearance of apoptotic bodies
and dendritic retraction. These alterations were not evident in
the presence of H. perforatum extract and fractions containing
bianthraquinones and flavonol glycosides. Accordingly with
these results, the authors concluded that H. perforatum alcoholic
extract and studied fractions have neuroprotective activity, which
can be of relevance on preventing amyloid-β peptide neuronal
degeneration. The senile plaques, in Alzheimer’s disease, are
also enriched with reactive microglia and astrocytes (Akiyama
et al., 2000). As immunocompetent cells of the brain, the
microglia are able to counteract the deleterious effects of
amyloid-β in Alzheimer’s disease. Taking this in consideration
and amyloid β-peptide toxicity described above, Kraus et al.
(2007) investigated the effects of the peptide on cell viability
of microglia and a possible protective mode of action of
H. perforatum extract by studying the influence of a pretreatment
on cell survival. In BV2 and N11 cells (microglial cell lines)
pretreated with H. perforatum ethanolic extract 50–100 µg/mL,
the cell death evoked by treatment with amyloid-β(25−35) and
amyloid-β(1−40) was significantly attenuated in a dose-dependent
manner. It was concluded that treatment with H. perforatum
ethanolic extract may restore or improve microglial viability,
attenuating amyloid-β mediated toxicity in Alzheimer’s disease.
Regarding biochemical and neurotransmitter alterations in the
brain, this neurodegenerative disorder is characterized by a loss
of cholinergic markers butyrylcholine and acetylcholine that
are hydrolyzed butyrylcholinesterase and acetylcholinesterase,
respectively. Cholinesterases are an ubiquitous class of serine
hydrolases that hydrolyze choline esters with various efficiency
(Talesa, 2001). The inhibitory effects of ethyl acetate, methanol
and water H. perforatum extracts against butyrylcholinesterase
and acetylcholinesterase were, therefore, investigated. Methanol
extract was the one that, from the three tested, exerted
the highest acetylcholinesterase inhibition (49.54 ± 4.44%),
while the ethyl acetate extract had the best inhibition toward
butyrylcholinesterase (50.79 ± 3.07%). The water extract
presented no inhibitory effect in the tested concentrations (50–
200 µg/mL). Another enzyme that has become a research target
in neurodegenerative diseases investigation has been tyrosinase,
a multifunctional enzyme, involved in neuromelanin production
and damaged neurons associated with Parkinson’s disease. The
three H. perforatum extracts described above were also tested
against tyrosinase, and only the methanol extract was found to
have a low inhibitory effect (19.21± 1.44%; Asanuma et al., 2003;
Altun et al., 2013).
Hypericum perforatum’s neuroprotective activity has also been
investigated in association with other compounds. For instance,
a drug commonly used for the treatment of Parkinson’s disease
is bromocriptine, which is reported to have strong free radical
scavenging action in vivo and potent neuroprotective actions
(Muralikrishnan and Mohanakumar, 1998; Mohanasundari
et al., 2006). Due to several adverse effects of bromocriptine
monotherapy, Mohanasundari et al. (2006) evaluated the
combined effect of bromocriptine and H. perforatum alcoholic
extract against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), a neurotoxin, in mice. Lipid peroxidation increased
in the MPTP-treated group when compared to the control (in
91%). H. perforatum extract and bromocriptine alone lowered
lipid peroxidation (p < 0.05) and the combined treatment
showed even better results, when comparing with all the other
groups (control, H. perforatum and MPTP-treated groups;
p < 0.05). A mixture of Panax quinquefolius, Ginkgo biloba,
and H. perforatum was proven to enhance retinal ganglion cell
survival after axotomy, increasing the number of regenerating
retinal ganglion cell in 87%, 21 days after optic nerve transaction.
Effects of the herbal extracts mixture on the survival of
axotomized retinal ganglion cells 7 days after axotomy showed a
delay in cell death, offering, therefore, significant neuroprotection
(p < 0.01) versus optical nerve transaction (Cheung et al., 2002).
Axotomy-induced retinal ganglion cell death has been adopted
as an animal model in the investigation of neuronal death in
the CNS. It is known to be related to the activation of apoptotic
pathways (Cheung et al., 2008), like caspase-3 and -9 (Cheung
et al., 2004). When investigating the mechanisms underlying
a neuroprotective activity of the herbal mixture described,
Cheung et al. (2008) verified an apoptotic property, through
the inhibition of cell’s nuclear fragmentation, with no effect
on caspase-3 action, suggesting that the reduction of nuclear
fragmentation was not achieved by the limitation of caspase-3
activation. The mixture, nonetheless, reduced the percentage
of caspase-3-negative fragmented nuclei, though with no effect
in caspase-3-dependent nuclear fragmentation, suggesting an
inhibition by a caspase-3 independent pathway. Additionally,
an intravitreal injection with wortannin, a phosphoinositide-3
kinase (PI3K) inhibitor, abolished the neuroprotective effect of
the herbal mixture, indicating, according to the authors, that this
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effect was PI3K-dependent. It’s important to refer that PI3K–Akt
(Akt: protein kinase identified in the AKT virus [also known
as protein kinase B]) signaling pathway plays a critical role in
mediating survival signals in a wide range of neuronal cell types
(Brunet et al., 2001).
Since the removal of excessive ROS or suppression of their
generation by antioxidants may be effective in the prevention
of oxidative cell damage (Benedi et al., 2004), having therefore
a neuroprotective effect, the protective antioxidant properties of
H. perforatum will also be described.
El-Sherbiny et al. (2003) studied the effect of a dried
ethanolic H. perforatum extract on brain oxidative status of
naïve rats upon the administration of an amnesic dose of
scopolamine. When in doses equivalent to the ones used to treat
depression, the extract proven to inhibit brain malondialdehyde
(MDA) formation, modulating also the activity of GPx and
the glutathione levels without any alteration on any of the
measured oxidative stress indices, suggesting that low doses of
H. perforatum extract have antioxidant properties, protecting rat
brain from elevated oxidative status due to the administration
of antidepressants. These protective activities have also been
reported in a hydroethanolic standardized and ethanolic (Benedi
et al., 2004; Silva et al., 2005; Silva B.A. et al., 2008) extracts of
H. perforatum through a direct radical scavenging activity on 1,1-
diphenyl-2-pycryl-hydrazyl (DPPH) radical [EC50 = 109 µg/mL
(Benedi et al., 2004), 49.3 ± 1.05 µg/dwb/mL (Silva B.A. et al.,
2008), and 21 µg/dwb/mL (Silva et al., 2005)] and inhibition of
xanthine oxidase (XO) activity (at a concentration of 5 µg/mL
the reported inhibition of XO activity was by 16% with an
IC50 = 68.3 µg/mL), which may also contribute to the scavenging
action of the O2− radical by H. perforatum. According to these
findings, H. perforatum may have the ability to bind iron ions and
a moderate to high direct scavenging action for hydroxyl radical,
independent of any enzymatic activity (Benedi et al., 2004; Silva
et al., 2005; Silva B.A. et al., 2008). Besides these properties,
H. perforatum ethanolic and aqueous extracts has the ability to
inhibit stress induced by 2,2′-azo-bis(2-methylpropianamidine)
dihydrochloride (AAPH), an inductor of lipid peroxidation by
formation of peroxyl radicals [IC50 = 50.4 ± 2.57 µg/dwb/mL
(Silva B.A. et al., 2008) and 16.77 µmol of Trolox equivalent/g
of fresh weight (Zheng and Wang, 2001)] and scavenge nitric
oxide (NO) [through nitrite measurement, used as an estimate
for the NO content (Cheung et al., 2008; Silva B.A. et al., 2008)]
(10 µg/dwb/mL extract showed 78.7 ± 1.3% reduction of release
of nitrite) and hypochlorous acid (through the reduction of 5-
thio-2-nitrobenzoic acid (TNB; 50 µg/dwb/mL extract showed
17.1± 1.3% reduction in TNB oxidation; Silva B.A. et al., 2008).
As stated previously, Parkinson’s a neurodegenerative disease.
In patients suffering from this pathology a reduction of
mitochondrial complex I activity has been reported. Rotenone,
a pesticide and specific inhibitor of this complex, causes tissue
damage due to its toxic effect (Sanchez-Reus et al., 2007), with an
involvement of oxidative damage (Sherer et al., 2003). Taken this
in consideration, the potential antioxidant protective effect of a
standardized extract of H. perforatum against rotenone-exposed
rats was investigated. The extract was tested on brain MDA,
GPx, CAT, MnSOD, and CuZnSOD expression and activities.
Pretreatment of rats with H. perforatum extract before insult
with rotenone resulted in an antioxidant activity with a decrease
in brain MDA formation and an increase of SOD, CAT, and
GPx levels. Regarding enzyme activities, H. perforatum extract
recovered brain mRNA levels of SOD and GPx, altered by
rotenone. In the case of CAT, pretreatment with the extract
also revealed an antioxidant effect reducing mRNA levels of the
enzyme elevated after rotenone administration, but this result
was different from those of activity (Sanchez-Reus et al., 2007).
This could be explained by an up-regulation of the relevant gene
expression, protecting therefore the cell from rotenone toxicity
(Alia et al., 2006).
Similarly to neuroprotective, also antioxidant properties
of H. perforatum extracts have been tested in combined
treatment regimens. When in simultaneous administration with
bromocriptine and after an insult with MPTP, restoration of
CAT, SOD, reduced glutathione (GSH), and GPx levels (CAT –
0.19 ± 0.01 to 0.57 ± 0.02; SOD – 1.97 ± 0.12 to 3.51 ± 0.08;
GSH – 0.28± 0.02 to 0.53± 0.02; GPx – 8.6± 0.02 to 12.0± 0.07)
to near normal (CAT – 0.58 ± 0.01; SOD – 3.83 ± 0.02; GSH –
0.62 ± 0.01; GPx –12.21 ± 0.17) was verified (Mohanasundari
et al., 2006). The herbal mixture of P. quinquefolius, G. biloba,
and H. perforatum described previously also exhibited anti-
oxidant activity, mainly NO scavenging property, by lowering
NO content in axotomized retinas [treatment with 30 mg of the
mixture significantly lowered the amount of nitrite (p < 0.05)
versus PBS-treated control group] without affecting NO synthase
activity (Cheung et al., 2008).
Neuroprotective Activity of Hypericum
perforatum Major Compounds
Hypericum perforatum’s major compounds are described as
neuroprotective in several studies, being this activity related with
direct pathways, such as an in vitro and in vivo cytoprotective
effect and indirect pathways, particularly through its antioxidant
properties.
Quercetin
Quercetin, whose ability to interact with multiple cellular targets
is likely the basis of its therapeutic activity (Dajas, 2012) has
been described to protect against several insults, such as H2O2
(Dok-Go et al., 2003; Arredondo et al., 2004, 2010; Heo and Lee,
2004; Suematsu et al., 2011), linoleic acid hydroperoxide (LOOH;
Sasaki et al., 2003), 6-hydroxydopamine (6-OHDA; Zhang et al.,
2011), and tert-butylhydroperoxide (t-BOOH; Silva J.P. et al.,
2008), in PC12 cells (Sasaki et al., 2003; Arredondo et al., 2004;
Heo and Lee, 2004; Silva J.P. et al., 2008; Zhang et al., 2011),
primary cultured rat cortical cells (Dok-Go et al., 2003) and rat
cerebellar granule neurons (Arredondo et al., 2010) and human
neuronal SH-SY5Y cells (Suematsu et al., 2011). In the first case,
it’s described a cytoprotective action of quercetin 25 and 50 µM
and 30–100 µM against H2O2 200 and 400 µM (Arredondo et al.,
2004; Heo and Lee, 2004), respectively, in PC12 cells. Similar
effects were described, for primary cultured rat cortical cells, with
quercetin at concentrations of 3 and 10 µg/mL, facing a H2O2-
injury at 100 µM (IC50 = 4.1 µg/mL; Dok-Go et al., 2003).
In primary rat cerebellar granule neurons a pretreatment with
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quercetin 25 µM significantly protected (p < 0.001) the cells
from H2O2-injury at 60 µM. These findings were supported by
morphological analysis of the cells (Arredondo et al., 2010). Heo
and Lee (2004) also studied quercetin’s ability to block H2O2-
induced membrane damage, verifying a significantly protective
effect of this flavonol (p < 0.05). In human neuronal SH-SY5Y
cells, quercetin increased the viability of H2O2-treated cells in a
concentration dependent manner, becoming about 67% of that of
the vehicle-treated ones at 100 µM. There were also suppressed
H2O2-induced apoptotic features, such as DNA fragmentation,
by co-treatment with quercetin, in a concentration dependent
manner. In addition, quercetin suppressed the caspase cascade
and pro-apoptotic Bax gene expression and increased anti-
apoptotic Bcl-2 gene expression (Suematsu et al., 2011).
Regarding LOOH insult, protective effects were reported in
undifferentiated and differentiated PC12 cells with quercetin 25
and 50 µM, respectively, in pre- and co-incubation regimens
(Sasaki et al., 2003). Pretreatment with quercetin 12.5–200 µM
protected PC12 cells against 6-OHDA-induced damage (at a
concentration of 1 mM) in a dose-dependent manner and
significantly reduced (p < 0.05) the LDH leakage caused by the
neurotoxin. Likewise, quercetin prevented 6-OHDA-induced cell
apoptosis and attenuated 6-OHDA-induced NO over-production
and iNOS over-expression. Morphological analysis of the cells
treated with 6-OHDA revealed the presence of bright condensed
dots, apoptotic bodies. There was also verified a reduction in
colony density and cell size. Pretreatment with quercetin 25, 50,
and 100 µM significantly attenuated nuclear condensation and
at higher concentrations (50 and 100 µM) inhibited 6-OHDA-
induced colony reduction and cell shrinkage (Zhang et al., 2011).
Regarding NO production, it’s believed that its augment and
consequent iNOS induction plays an important role in the
initial phase of 6-OHDA-induced neuro-damage in in vitro and
in vivo models (Lin et al., 2007). Taking this in consideration,
Zhang et al. (2011) with a mechanistic study, tested the effect
of quercetin on 6-OHDA-induced NO over-production and
iNOS over-expression in PC12 cells, concluding that quercetin
attenuated NO over-production via down-regulation of iNOS
over-expression in 6-OHDA-treated cells. Silva J.P. et al. (2008)
studied the protective effect of quercetin against t-BOOH-
induced strand breaks. When added simultaneously with the
insult, quercetin’s protective effect was significantly increased
(p ≤ 0.001, compared with t-BOOH 200 µM), when comparing
with a co-incubation regimen (p ≤ 0.01).
Likewise, pretreatment of HT22 cells with quercetin 5
and 10 µM significantly attenuated amyloid-β(1−42)-induced
cytotoxicity (p < 0.001) and decreased 4-hydroxinonenal levels
(an index of lipid peroxidation), in comparison to control
(p < 0.001). Low doses of quercetin (5 and 10 µM) also
mitigated morphological alterations induced by amyloid-β(1−42),
characterized by vacuolated soma and fragmented neurites,
membrane blebbings and cell shrinkage, inhibiting, therefore
amyloid-β(1−42)-induced apoptotic cell death (Ansari et al.,
2009).
Liu et al. (2013) studied the effect of quercetin in the
neurovascular unit (NVU) and its underlying mechanisms.
The NVU comprises cerebral blood vessels and surrounding
cells, such as astrocytes, neurons, and pericytes (Abbott,
2002) where the receptor for advanced glycation end products
(RAGE) and low density lipoprotein receptor related protein-
1 play an important role in the control of amyloid-β
levels in the brain (Deane et al., 2009), maintaining it.
After injecting amyloid-β(25−35), quercetin, in concentrations
from 5 to 40 mg/kg, was orally administrated, in male
Kunming mice, for 8 days. Quercetin treatment improved the
learning and memory capabilities and conferred neurovascular
coupling protection, involving maintenance of the NVU
integrity, reduction of neurovascular oxidation, modulation of
microvascular function, improvement of cholinergic system,
and regulation of neurovascular RAGE signaling pathway. The
authors conclude on a possible quercetin mechanism through
reduction of oxidative damage, inactivation of RAGE-mediated
pathway and preservation of cholinergic neurons (Liu et al.,
2013).
Silva B. et al. (2008) investigated the effects of H. perforatum’s
phenolic compounds, such as quercetin, against neuronal
excitotoxicity and mitochondrial disfunction. Quercetin 10 µM
significantly reduced neuronal death due to kainate and NMDA-
insult (p < 0.05). The authors correlated this protection with
prevention of toxic-induced delayed calcium deregulation and
the maintenance of mitochondrial electric potential. Quercetin
10 µM was also able to reduce mitochondrial lipid peroxidation
and loss of mitochondrial transmembrane electric potential
caused by oxidative stress ADP plus Fe-induced.
In Sprague-Dawley rats, with Parkinsonism induced by
the neurotoxin 6-OHDA, a 14 days treatment with quercetin
significantly increased the striatal dopamine (p< 0.05) by 34,56%
and decreased the striatal protein carbonyl level (p < 0.05)
by 49.69% compared with levels found in the 6-OHDA
treated group (Haleagrahara et al., 2011). The increase of
protein carbonyls is a proof of oxidatively damaged proteins,
characteristic of Parkinson’s disease (McNaught et al., 2003). In
zebrafish, considered a good model to study disorders of the
dopaminergic system (Rink and Wullimann, 2001), co-treatment
with quercetin (6 or 12 µM) significantly inhibited 6-OHDA-
induced dopaminergic neuron loss (p < 0.05). However, there
was no reversion of the neuron loss by quercetin after a 48 h
exposure to 6-OHDA, what could be attributed to the poor
permeability of quercetin across the blood–brain-barrier (Ossola
et al., 2009; Zhang et al., 2011).
Regarding its antioxidant properties, quercetin has been
shown to have an excellent in vitro antioxidant activity and
it is considered the most potent scavenger of ROS, RNS,
and peroxynitrite of the flavonoid family (Boots et al., 2008).
In human hepatoma HepG2 cell line, quercetin 50 and
100 µM evoked a significant increase of intracellular GSH
(76 ± 6 ng/mg/protein and 83 ± 7 ng/mg/protein, respectively),
after 4 h treatment (p < 0.05; Alia et al., 2006), which can be
expected, assuming the preparation of the cell against a potential
oxidative insult (Myhrstad et al., 2002). This flavonol was also
able to inhibit significantly ROS generation (p< 0.05), after insult
with t-BOOH, therefore preventing or delaying conditions which
favor oxidative stress in the cell (Alia et al., 2006). Increase of
intracellular GSH has also been reported in rat primary cerebellar
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granule neurons, after a 24 h quercetin 25 µM pretreatment
(146.3 ± 12%, in comparison to control; Arredondo et al., 2010).
Regarding GSH synthesis, it’s important to refer the role of the
Nuclear factor erythroid 2 related factor 2 (Nrf2)-dependent
cytoprotective pathway in the induction of gene expression of
enzymes involved in it. Taking into account that Nrf2 is a
translocation factor, it is essential that it translocates to the
nucleus in order to transactivate (Myhrstad et al., 2002; Zhang
et al., 2013). Consequently, Liu et al. (2013) studied the activity
of quercetin in nuclear translocation of Nrf2 in neurons. By the
use of immunocytochemistry, there was verified that quercetin-
treated cultures presented a major Nrf2 signal in both cytoplasm
and, particularly, nucleus. The authors conclude that quercetin
has the ability to cause nuclear translocation of Nrf2 in neuronal
cultures, therefore activating the Nrf2 cytoprotective signaling
pathway. Similarly, quercetin’s protective activity was verified by
the inhibition of the oxidative injury induced by xanthine/XO
in primary cultured rat cortical cells (quercetin 10 µg/mL and
IC50 = 5.5 µg/mL; Dok-Go et al., 2003).
Quercetin prevents DNA single strand breakage and
cytotoxicity, in U937 lymphoblast human cell line, caused
by t-BOOH through its iron chelation properties. In fact,
quercetin 100 µM and desferroxamine, an iron chelator (used
as a control for this activity) prevented DNA cleavage generated
by H2O2, whereas antioxidants trolox and N,N′-diphenyl-1,4-
phenylenediamine were not efficient (Sestili et al., 1998). Metallic
ions chelating is also involved in quercetin’s ability to diminish
and prevent the oxidative hepatic damage produced by ethanol,
besides interrupting the chain reaction that takes place on the
lipid membrane. Pre-treatment with quercetin in mices treated
with chronic doses of ethanol is more effective for CAT, selenium
dependent-GPx, total GPx and GSH, which can be explained by
a possible promotion of the antioxidant endogenous defenses
(Molina et al., 2003).
According to Inal and Kahraman (2000), quercetin may be
useful in reducing or preventing photobiologic damage, caused
by ultraviolet A light, since it significantly decreases MDA levels
(p < 0.05 and p < 0.001) and increases antioxidant defenses,
namely SOD and CAT activities (p < 0.001), in Sprague-Dawley
rats. In the same animal model, with Parkinsonism induced by
6-OHDA, a 14 days treatment with quercetin partially restored
GSH levels, increasing it by 97.88% as compared with GSH in rats
treated only with 6-OHDA (p < 0.05; Haleagrahara et al., 2011).
Antioxidant activities of quercetin have also been reported
through its antiradical activity on DPPH [EC50 = 8.30± 1.03 µM
(Silva B.A. et al., 2008), 11.34 ± 0.04 µM (Ramos et al., 2008)
and 10.37 ± 1.53 µg/mL (Dok-Go et al., 2003)] and AAPH
(EC50 = 29.4± 2.29 µM), lipid peroxidation inhibition potential
(EC50 = 0.08 ± 1.90 µM; Silva B.A. et al., 2008) and inhibitory
effect on NO synthase in a concentration-dependent manner,
determined in rat cerebral homogenate and blood (IC50 = 63.06
and 57.54 µM, respectively; Luo et al., 2004).
Despite its beneficial activities, quercetin has also been
reported to have toxic effects (Dok-Go et al., 2003; Arredondo
et al., 2004, 2010; Boots et al., 2008; Ansari et al., 2009),
being consequently important, to define, the therapeutical
concentration of this compound (Ansari et al., 2009), for
different pathologies, in order to maximize positive and minimize
deleterious effects. It’s also relevant to refer that studies of in vivo
quercetin’s neuroprotective activity remains controversial which
can be due to the failure to examine prolonged exposures to
micromolar levels of the flavonol and a required unattainable
in vivo concentration (Ossola et al., 2009; Dajas, 2012).
Hyperoside
Hyperoside is the main active component of H. perforatum
(Silva B.A. et al., 2008). Despite this, its neuroprotective activity
has not been explored. Liu et al. (2005) evaluated hyperoside’s
ability to prevent ROS generation and diminishing neuronal
damage, in PC12 cells. Alone, hyperoside promoted the growth
rate of the cells among the concentrations of 10–180 µg/mL,
markedly between 10 and 120 µg/mL. As for its cytoprotective
activity, hyperoside was effective preventing t-BOOH- and
H2O2-induced toxicity, in a dose dependent manner, with the
best improvement for 175% of control group at 160 µg/mL
and 177% of control group at 100 µg/mL. These results were
concordant to those of flow cytometry assay, where apoptotic
cells formed via t-BOOH- and H2O2-induced toxicity were
measured (sub-G1 peak). Hyperoside (160 and 100 µg/mL)
attenuated cell death via apoptosis to 1.0 and 1.3%, respectively
(Abbott, 2002). Protective properties of hyperoside in amyloid-
β(25−35)-induced toxicity, in primary cortical rat neurons, were
also studied. After exposure to amyloid-β(25−35) (20 µM) for
24 h cell viability decreased to 63.1 ± 3.2%. Pretreatment for
30 min with hyperoside 5, 10, and 20 µM significantly increased
cell viability [p < 0.05 for 5 and 10 µM and p < 0.01 for
20 µM, in comparison with amyloid-β(25−35) treatment group].
Morphological analysis of the cells supported these results,
with an effective reversion of amyloid-β(25−35) neurite injury
(observed as neurite loss and cleavage) after pretreatment with
hyperoside (2.5, 5, 10, and 20 µM). Apoptosis was also reverted
in a dose dependent manner, after pretreatment with hyperoside,
by reversing the amyloid-β-induced mitochondrial disfunction,
including mitochondrial membrane potential decrease, ROS
production, and mitochondrial release of cytochrome c. Caspase-
9 and caspase-3 activities were also significantly inhibited
(p < 0.01), after pretreatment with hyperoside (5, 10, and
20 µM) and amyloid-β(25−35)-induced injury. Further study
indicated that hyperoside can activate PI3K/Akt signaling,
resulting in inhibition of Bad–BclXL interaction, without
intervening in Bad–Bcl-2 interaction. It was concluded that
hyperoside can protect amyloid-β(25−35)-induced injury in
primary cultured cortical neurons via PI3K/Akt/Bad/BclXL-
regulated mitochondrial apoptotic pathway (Zeng et al., 2011).
In the same biological model, the neuroprotective activity of
hyperoside was investigated, by using an in vitro ischemic model
of oxygen-glucose deprivation followed by reperfusion (OGD-R).
Pretreatment with hyperoside (3, 10, 30, and 100 µM) for 24 h
was able to significantly protect cultured cortical neurons from
OGD-R injury (p < 0.05 for 3 µM and p < 0.01 for 10, 30, and
100 µM, in comparison to OGD-R group). In order to investigate
the protective effect of hyperoside in neuronal excitotoxicity
that can occur after OGD-R injury, cultured cortical neurons
were exposed to glutamate 200 µM combined with glycine
Frontiers in Plant Science | www.frontiersin.org 8 July 2016 | Volume 7 | Article 1004
fpls-07-01004 July 8, 2016 Time: 16:51 # 9
Oliveira et al. Neuroprotective Activity of Hypericum perforatum
10 µM for 2 h, followed by 24 h reperfusion. Pretreatment with
hyperoside 24 h prior to the glutamate-exposure reversed the
degradation of cell viability in a concentration dependent manner
and significantly increased the neuronal survival rate (p < 0.05
for 1 µM and p < 0.01 for 3, 10, 30, and 100 µM in comparison
to glutamate-exposure group). Hyperoside (10 µM) also relieved
NMDA receptor-induced [Ca2+]i elevation (p < 0.01, compared
to NMDA group). NMDA receptor mediates Ca2+ influx, which
is responsible for excitotoxicity (Liu et al., 2012). As for possible
related mechanisms, the authors describe attenuation of CaMKII
phosphorylation caused by OGD-R lesions. Hyperoside also
lessened iNOS expression induced by OGD-R via inhibition of
Nf-kB activation and ameliorated extracellular signal-regulated
kinase, c-Jun NH2-terminal kinase, and Bcl-2 family-related
apoptotic signaling pathways (Liu et al., 2012), related to NO
signaling pathway.
As for its antioxidant activity, hyperoside is known for its
ROS scavenging activity (Liu et al., 2005). It has active antiradical
activity on DPPH (EC50 = 6.38 ± 1.06 µM) and APPH
(EC50 = 11.5± 1.76 µM), lipid peroxidation inhibition potential
(EC50 = 5.37 ± 1.05 µM; Silva B.A. et al., 2008) and inhibitory
effect on NO synthase in a concentration-dependent manner,
determined in rat cerebral homogenate and blood (IC50 = 56.23
and 158.49 µM, respectively; Luo et al., 2004).
Quercitrin
Quercitrin is thought to possibly overcome quercetin in
its antioxidant and neuroprotective activity due to its high
bioavailability in the digestive track (Hollman et al., 1995).
Despite this, few studies have been published focusing on
the neuroprotective activity of quercitrin. Rattanajarasroj and
Unchern (2010) studied the neuroprotective effects of quercitrin
on amyloid-β(25−35)-induced injury in cultured hippocampal
rat neurons, as well as its possible mechanisms. Co-incubation
of quercitrin (50 and 100 µM) and amyloid-β(25−35) for 72 h
significantly increased cell viability (p < 0.01), in comparison
to cells only subjected to amyloid-β(25−35) injury. These results
were supported by the analysis of cell death, through LDH
leakage assay. Here and in all experimental conditions, the
magnitude of cell death was correlated with the percentage of cell
viability in a complementary manner. Neuroprotective potential
of quercitrin, using a rat primary-isolated retinal ganglion cells
cultured under three types of stress conditions: hypoxia, excessive
glutamate levels, and oxidative stress, was also evaluated. After
12 h of hypoxia stress, the retinal ganglion cells survival
rate was reduced in cells without quercitrin to 55.5 ± 10%.
Treatment with quercitrin 100 nM and 1 µM significantly
increased retinal ganglion cell viability (p< 0.05; Nakayama et al.,
2011). Regarding glutamate-induced cell death similar results
were verified, with the quercitrin-treated retinal ganglion cells
[increase in cell viability, in the same concentrations referred
above (p < 0.05)].
As for its antioxidant activity, co-exposure of quercitrin
(50 and 100 µM) and amyloid-β(25−35) for 72 h significantly
decreased cellular lipid peroxidation in a concentration
dependent manner (p < 0.05, compared to amyloid-β(25−35)-
exposure group). There were, however, no significant effects
on amyloid-β(25−35)-induced ROS accumulation. It was
hypothesized that a long exposure of cells to quercitrin could
alter intracellular antioxidant defense system, including the
production of GSH, SOD, and GPx. However, only GPx
significantly increased its activity after co-exposure to quercitrin
and amyloid-β(25−35) (p < 0.05; Rattanajarasroj and Unchern,
2010).
Antioxidant activities of quercitrin have also been reported
through its antiradical activity on DPPH (EC50 = 13.0 ±
1.10 µM) and lipid peroxidation inhibition potential (Wagner
et al., 2006; Silva B.A. et al., 2008; EC50 = 7.33 ± 1.16 µM; Silva
B.A. et al., 2008).
Rutin
Neuroprotective properties of rutin, a flavonoid with a wide
range of biological activities, have been investigated. Wang et al.
(2012) studied the interference of rutin in the pathogenic factors
of Alzheimer’s disease. Morphological analysis of amyloid-β
fibrillization revealed that amyloid-β42 co-incubation with rutin
200 µM inhibited by more than 95% fibril formation. In
SH-SY5Y cells rutin 20 µM significantly inhibited amyloid-
β42 cytotoxicity (p < 0.05), also restoring cells fluorescent
intensity ratio value in a concentration-dependent manner, which
is, according to the authors, indicative of an attenuation of
amyloid-β42-induced mitochondrial dysfunction. In order to
determine rutin’s ability to protect against an oxidative damage,
SH-SY5Y cells were treated with amyloid-β42, in the presence
and absence of rutin. The flavonoid decreased amyloid-β42-
induced ROS production in a concentration dependent-manner,
with a significant inhibition when rutin 8 µM was employed
(p < 0.05). Likewise, MDA levels were significantly decreased
with rutin 0.8 and 8 µM (p < 0.05). Regarding the regulatory
effect of rutin on GSH content, rutin 0.8 and 8 µM increased,
in a concentration-dependent manner, GSH content of BV-2
microglial cells and decreased GSSG levels. The GSH/GSSG
ratios were also decreased by amyloid-β42 and increased with the
addition of rutin 8 µM (p < 0.05). Rutin’s effects on aldehyde
dehydrogenase 2 (enzyme which metabolizes acetaldehyde into
non-toxic acetate; ALDH2) activity in HT22 cells were also
studied. Pretreatment with rutin 1 µg/mL, significantly inhibited
ethanol-induced cell death (p < 0.01). Co-treatment with rutin
also significantly reversed ethanol-increased Bax (p < 0.05,
compared with ethanol), caspase 3 activity, and decreased Bcl-
2 and Bcl-xL protein expression (p < 0.01, compared with
ethanol). In order to clarify the mechanisms involved in rutin’s
protective effects, an ALDH2 inhibitor, daidizin, was employed.
Taking into account that pretreatment with rutin also lowered
cytochrome c expression (involved in ethanol-induced apoptosis
in HT22 cells; p < 0.01) and increased ALDH2 expression, it is
concluded that rutin protects HT22 cells against ethanol-induced
neurotoxicity by increasing ALDH2 activity (Song et al., 2014).
Nakayama et al. also investigated the effects of rutin under the
three types of stress conditions mentioned above. Regarding
hypoxia stress, the retinal ganglion cells survival rate was reduced
in cells without rutin 56.0 ± 3.1%. Treatment with rutin 1, 10,
and 100 nM significantly increased retinal ganglion cell viability
(p < 0.05). As for glutamate-induced cell death similar results
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were verified [increase in cell viability, in the same concentrations
referred above (p < 0.05)]. Under oxidative stress conditions,
the activity of caspase-3 and calpain were studied, in order to
investigate the effect of rutin in apoptotic and necrotic cell death
signaling, respectively. Calpains are a family of cytosolic cysteine
proteinases whose enzymatic activities depend on Ca2+ and are
believed to function in various biological processes, including cell
death, more specifically, necrosis. Rutin at final concentrations
of 1, 10, and 100 nM showed significant reduction of caspase-3
activity under hypoxia and by glutamate stress (p < 0.05) and
of calpain activity by oxidative stress (p < 0.05; Goll et al., 2003;
Nakayama et al., 2011).
Khan et al. (2009) investigated the protective effects of rutin
on cerebral ischemia on Wistar rats. Pretreatment with rutin
(25 mg/kg, for 21 days) protected the animals from motor
deficit and lead to recovered motor coordination (p < 0.05,
in comparison with the lesion group), improving, therefore,
the neurological outcomes. It was also verified a significant
attenuation (p < 0.05) on thiobarbituric acid reactive species,
H2O2 levels and protein carbonyl content, in comparison to
lesioned rats. Morphological analysis of rats’ brains revealed that
activation of p53 up-regulation (associated with neuronal cell
death in cerebral ischemia) was also attenuated by rutin. These
results lead the authors to conclude that rutin offered significant
protection on middle cerebral artery occlusion rats, probably
due to inhibition of neurological deficit, lipid peroxidation,
p53 expression and increase in endogenous antioxidant defense
enzymes (data shown downward), evoking neuroprotection to
the degenerating dopaminergic neurons (Khan et al., 2012).
Taking the previous results into consideration, Khan et al.
(2012) investigated the neuroprotective activity of rutin on 6-
OHDA-induced Parkinson’s disease in rats. Similar results were
obtained concerning the rutin’s protective activity, leading the
authors to suggest that the consumption of rutin may have
positive effects on the prevention on neurological disorders,
such as Parkinson’s disease. Regarding Alzheimer’s disease and
in following the study of Wang et al. (2012) and Xu et al.
(2014) investigated the effects of rutin on APPswe/PS1dE9
transgenic mice. These animals overproduce human amyloid-β40
and amyloid-β42, also developing progressive cerebral β-amyloid
deposit and learning and memory impairment, being considered
animal models for Alzheimer’s disease (Garcia-Alloza et al.,
2006). Oral administration of rutin (100 mg/kg for 6 weeks)
significantly attenuated memory deficits, associated with the
reduction in β-amyloid oligomer formation. It also improved
spatial memory (p< 0.05, compared with disease’s control group)
in transgenic mice. Similarly to in vitro studied performed by
Wang et al. (2012), there was also reported a protective activity
by rutin in the attenuation on β-amyloid-induced oxidative stress
and lipid peroxidation. Rutin was also able to reduce neuro-
inflammation in transgenic mice by attenuating microgliosis and
astrocytosis (Xu et al., 2014).
Rutin is considered to have powerful antioxidant capacity
against several antioxidant in vitro systems, being a concentration
dependent property (Yang et al., 2008). Alike quercetin, in HepG2
cells, rutin 100 µM significantly increased intracellular GSH
(52± 2 ng/mg/protein; p< 0.05). Despite its similar effects, rutin
demonstrated to be less active than quercetin, which could be
related to its lower bioavailability (Alia et al., 2006).
As to in vivo studies, antioxidant activities have also been
reported (La Casa et al., 2000; Kamalakkannan and Stanely
Mainzen Prince, 2006; Khan et al., 2009; Xu et al., 2014).
Pre-treating Wistar rats with rutin (25 mg/kg, for 21 days)
significantly restored (p< 0.05) GSH, GPx, GR, SOD, and CAT in
hippocampus (GPx – from−35.69 to 31.31%; GR – from−45.12
to 48.65%; SOD – from−45.18 to 39.42%; CAT – from−54.28 to
66.96%) and frontal cortex (GPx – from −41.53 to 45.56%; GR –
from −46.36 to 36.53%; SOD – from −50.51 to 68.73%; CAT –
from −55.95 to 43.80%), in comparison to lesioned rats (Khan
et al., 2009).
Antioxidant activities of rutin have also been reported through
its antiradical activity on DPPH [Ramos et al., 2008; Silva B.A.
et al., 2008; Yang et al., 2008; EC50 = 11.3 ± 1.06 µM (Silva
B.A. et al., 2008) IC50 = 18.27 ± 0.62 µM (Ramos et al., 2008)],
AAPH [EC50 = 31.5 ± 4.93 µM (Silva B.A. et al., 2008)], lipid
peroxidation inhibition potential (EC50 = 8.98 ± 1.03 µM) and
scavenging of superoxide radicals (IC50 = 0,13 mg/mL) and
hydrogen peroxide (IC50 = 24 µg/mL; Yang et al., 2008).
Hypericin
The effect of hypericin (neuroprotection or apoptosis) on the
transcription factor NF-kB, which is involved in regulation of
genes relevant in several cellular processes, like neuronal survival
and inflammatory response, has been accessed (Kaltschmidt
et al., 2002). One hour treatment of cerebellar granule cells
with 0.1 µM hypericin resulted in activation of NF-kB, which
is further enhanced with 1 or 10 µM hypericin. Despite of
the hypothesis that long-lasting activation of the transcription
factor would result in neuroprotection, a 24 h treatment with
different hypericin concentrations lead to a loss of the NF-
kB activation previously observed. Basing on these results the
authors investigated the effect of hypericin in Fe2+ ion-induced
cell death. While low concentrations of hypericin (0.1 and 1 µM)
had no effect on cell survival, 10µM exerted cell death up to 100%
after 24 h treatment, having therefore a synergistic effect with
Fe2+. It was concluded that stimulus like hypericin, depending on
the gene promoters that are activated, may have a neuroprotective
therefore anti- or apoptotic activity (Kaltschmidt et al., 2002).
Low antioxidant activity of hypericin have been reported
through its lipid peroxidation inhibition potential (EC50 = 21.0
± 2.86 µM; Silva B.A. et al., 2008).
Kaempferol
Filomeni et al. (2012) studied the ability of kaempferol to protect
SH-SY5Y cells and primary neurons from rotenone-induced
toxicity. Pre-treating cells with kaempferol 30 µM for 1 h prior
to a 1 µM rotenone-insult significantly counteracted rotenone-
induced toxicity (p < 0.01). Microscopic morphologic analysis
indicated that kaempferol was able to inhibit rotenone-induced
round shape phenotype and cell detachment, characteristics of
apoptotic process. At a molecular level, kaempferol was proven to
significantly inhibit rotenone-induced caspase-3 and -9 cleavage
(p < 0.001). Kaempferol was also able to preserve and restore
mitochondrial function upon rotenone-mediated challenge, at
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least if provided before caspases activation, within upon 12 h.
Underlying kaempferol protective activity was its autophagic’s
ability, prior demonstrated in carcinoma cells by altering cellular
energetics. The authors conclude that this maintained at lower
doses and protects neuronal cells against from rotenone-induced
toxicity. Note that autophagy has been observed to be deregulated
in Parkinson’s disease (Chu et al., 2009; Filomeni et al., 2010,
2012).
Kaempferol was also investigated for its ability to protect
neurons from excitotoxicity and mitochondrial dysfunction.
Results were similar to those of quercetin, what lead the authors
to conclude for a possible neuroprotective activity induced by the
antioxidant properties of these compounds (Silva B. et al., 2008).
Antioxidant activities of kaempferol have been reported
through its antiradical activity on DPPH (EC50 = 21.3 ±
1.04 µM) and lipid peroxidation inhibition potential
(EC50 = 0.69± 1.62 µM; Silva B.A. et al., 2008).
Biapigenin
Biapigenin is a sparingly studied compound for its possible
neuroprotective activity. It was studied (as well as quercetin and
kaempferol) its ability to protect neurons from excitotoxicity and
mitochondrial dysfunction. Besides the results already described,
that were similar for biapigenin, this biflavone significantly
affects mitochondrial bioenergetics (p < 0.001, in comparison
to insult) and decreased the mitochondria’s ability to accumulate
calcium (p < 0.05, in comparison to control; Silva B. et al.,
2008). Biapigenin modulates the mitochondrial permeability
transition pore, reducing calcium burden and contributing
against excitotoxic insults (Silva et al., 2010).
Antioxidant activities of biapigenin have been reported
through its lipid peroxidation inhibition potential (EC50 = 5.10
± 1.11 µM; Silva B.A. et al., 2008).
Hyperforin
Hyperforin is the major lipophilic constituent of H. perforatum
(Albert et al., 2002) and considered the major active compound
for the anti-depressant activity (Singer et al., 1999).
Dinamarca et al. (2008) studied the ability of a hyperforin
synthetic analog, tetrahydroperforin (IDN 5706) on the reduction
of β-amyloid deposition and the improvement of spatial
learning acquisition, destabilizing amyloidβ-acetylcholinesterase
interaction. It is important to refer that in vivo and in vitro
studies are indicative of an enhancement of amyloidβ aggregation
and amyloid fibril formation by acetylcholinesterase (Dinamarca
et al., 2008). This study showed that IDN 5706 decreased the
formation of β-amyloid fibrils in vitro, depolymerizing them.
An oral administration of 1.25 mg/kg/day, for 7 days, in
rats, improved learning ability from the second day onward.
Additionally the memory of the learned responses acquired
during the administration time and training was retained after
9 days without further treatment or training. Klusa et al.
(2001) also verified that on mice, a single dose of 1.25 mg/kg
of hyperforin improved memory acquisition and consolidation
and completely reversed scopolamine-induced amnesia. The
authors concluded that hyperforin possesses memory enhancing
properties, being potentially considered as an antidementia
compound (Klusa et al., 2001).
In vivo and in transgenic mice, Dinamarca et al. (2008) verified
that IDN 5706 was able to remove the acetylcholinesterase
present in the plaques and improved the animal behavior,
indicating that the presence of the enzyme was correlated to the
behavioral impairment observed.
In a subsequent work, Inestrosa et al. (2011) studied the
in vivo effects of IDN 5706 on β-amyloid neurotoxicity using
young transgenic mice. Five months old mice were treated
for 10 weeks, tested for spatial memory and their brains
analyzed through several techniques. The authors reported that
IDN 5706 significantly reduced spatial memory impairments,
tau hyperphosphorylation, β-amyloid oligomer accumulation
and increased long-term potentiation, suggesting that this
compounds could be a novel pharmacological tool for the
treatment of Alzheimer’s disease (Inestrosa et al., 2011).
CONCLUSION
Hypericum perforatum has been used in traditional medicine
for several hundred years. Despite of not fully studied or
understood, the extract and isolated compounds of this plant have
demonstrated neuroprotective activities. Neuroprotection can be
achieved by a direct action on one or several mechanisms, such
as an anti-apoptotic effect, or indirectly, through antioxidant
properties. Chemically, structure-activity relationships suggest
that sugar side chain of flavonoids might be important for
neuroprotective activities (Nakayama et al., 2011) and multiple
hydroxyl groups confer these compounds substantial antioxidant
properties (Heim et al., 2002). Taken together, the data collected
suggests a protective effect of H. perforatum and some of its
major compounds in neurotoxicity, thus a possible beneficial
activity in neurodegenerative disorders, such as Alzheimer’s and
Parkinson’s disease. Nonetheless, further studies are needed to
fully understand and characterize the activity of this plant and
its compounds and its possible therapeutic activity.
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